Literature DB >> 11324930

Rheumatoid factors, anti-filaggrin antibodies and low in vitro interleukin-2 and interferon-gamma production are useful immunological markers for early diagnosis of community cases of rheumatoid arthritis. A preliminary study.

O Vittecoq1, F Jouen-Beades, K Krzanowska, I Bichon-Tauvel, J F Ménard, A Daragon, F Tron, X Le Loët.   

Abstract

OBJECTIVE: To determine whether measurements of different autoantibodies (Ab) and cytokines are useful to distinguish very early rheumatoid arthritis (RA) from other inflammatory rheumatisms.
METHODS: From a population-based recruitment, 32 patients with very early polyarthritis (median duration: 4 months) were studied. Evaluations at entry (M0), and at 6 (M6) and 12 months (M12). Ab tested: rheumatoid factors (RF) by agglutination methods and ELISA, antiperinuclear factor (APF), antikeratin Ab (AKA), anti-Sa and antinuclear Ab. Cytokine production (TNFalpha, IL2, IFNgamma, IL1beta, IL10) in whole blood cell culture (WBCC) was determined at M0. At M12, patients were classified as having RA (N = 15) or other rheumatic diseases.
RESULTS: At M0, AKA/APF and anti-Sa Ab frequencies were low, 13% and 7%, respectively. While most Ab detected at M0 persisted, others appeared during follow-up, particularly APF, which rose from 13 to 40% at M12. At M6, IgM-RF was detected in two RA patients exclusively by ELISA. AKA/APF were found to be highly specific markers for RA (100% specificity). At some time during follow-up, two RF-negative RA patients were AKA-positive. In two patients, AKA and APF were present at M0 before they satisfied ACR criteria. IL2 and IFNgamma production was significantly lower (P < 0.05) for RA patients.
CONCLUSION: AKA/APF and anti-Sa Ab were detected in community cases of very early RA. AKA/APF and RF detected by ELISA might contribute to an earlier diagnosis of RA. Low production of IFNgamma and IL2 in WBCC constituted a distinct immunopathological feature in very early RA patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11324930     DOI: 10.1016/s1297-319x(00)00244-x

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  5 in total

1.  Antibodies to mutated citrullinated vimentin in patients with chronic hepatitis C virus genotype IV infection-related arthropathy.

Authors:  M Zehairy; E Soliman; A Daghaidy
Journal:  Rheumatol Int       Date:  2011-11-09       Impact factor: 2.631

2.  Diagnostic and prognostic values of anti glucose-6-phosphate isomerase antibodies in community-recruited patients with very early arthritis.

Authors:  F Jouen; O Vittecoq; F Leguillou; I Tabti-Titon; J F Menard; O Mejjad; S Pouplin; P Boumier; P Fardellone; A Gayet; D Gilbert; F Tron; X Le Loët
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

3.  Diagnostic performances of anti-cyclic citrullinated peptides antibody and antifilaggrin antibody in Korean patients with rheumatoid arthritis.

Authors:  Suk Woo Choi; Mi Kyoung Lim; Dong Hyuk Shin; Jeong Jin Park; Seung Cheol Shim
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

4.  Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis.

Authors:  O Vittecoq; B Incaurgarat; F Jouen-Beades; J Legoedec; O Letourneur; D Rolland; G Gervasi; J F Ménard; A Gayet; P Fardellone; A Daragon; M Jolivet; X le Loët; F Tron
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

5.  Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative.

Authors:  P Machado; I Castrejon; W Katchamart; R Koevoets; B Kuriya; M Schoels; L Silva-Fernández; K Thevissen; W Vercoutere; E Villeneuve; D Aletaha; L Carmona; R Landewé; D van der Heijde; J W J Bijlsma; V Bykerk; H Canhão; A I Catrina; P Durez; C J Edwards; M D Mjaavatten; B F Leeb; B Losada; E M Martín-Mola; P Martinez-Osuna; C Montecucco; U Müller-Ladner; M Østergaard; B Sheane; R M Xavier; J Zochling; C Bombardier
Journal:  Ann Rheum Dis       Date:  2010-08-19       Impact factor: 19.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.